Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
作者信息
Jadvar Hossein, Calais Jeremie, Fanti Stefano, Feng Felix, Greene Kirsten L, Gulley James L, Hofman Michael, Koontz Bridget F, Lin Daniel W, Morris Michael J, Rowe Steve P, Royce Trevor J, Salami Simpa, Savir-Baruch Bital, Srinivas Sandy, Hope Thomas A
机构信息
Department of Radiology, University of Southern California, Los Angeles, California;
Department of Molecular and Medical Pharmacology, University of California, Los Angeles, California.
出版信息
J Nucl Med. 2022 Jan;63(1):59-68. doi: 10.2967/jnumed.121.263262. Epub 2021 Sep 30.
Abstract
摘要
相似文献
1
Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.
J Nucl Med. 2022 Jan;63(1):59-68. doi: 10.2967/jnumed.121.263262. Epub 2021 Sep 30.
2
Writing PET into existence.
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):7-10. doi: 10.1007/s00259-013-2573-x. Epub 2013 Sep 27.
3
Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.
Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4.
4
The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer.
Asian J Androl. 2021 Jan-Feb;23(1):1-2. doi: 10.4103/aja.aja_35_20.
5
Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Eur Urol Oncol. 2018 May;1(1):78-82. doi: 10.1016/j.euo.2018.03.010. Epub 2018 May 15.
6
Will GRPR Compete with PSMA as a Target in Prostate Cancer?
J Nucl Med. 2017 Dec;58(12):1883-1884. doi: 10.2967/jnumed.117.198192. Epub 2017 Sep 28.
7
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
8
Prostate-Specific Membrane Antigen: The Target of the Decade, from Biochemical Recurrence to Widespread Adoption.
J Nucl Med. 2020 Dec;61(Suppl 2):246S-247S. doi: 10.2967/jnumed.120.252213.
9
68Ga-Prostate-Specific Membrane Antigen-Avid Tubercular Lesions Mimicking Prostate Cancer Metastasis on Simultaneous Prostate-Specific Membrane Antigen PET/MRI.
Clin Nucl Med. 2017 Dec;42(12):e509-e510. doi: 10.1097/RLU.0000000000001874.
10
PSMA-negative prostate cancer and the continued value of choline-PET/CT.
Nuklearmedizin. 2020 Feb;59(1):33-34. doi: 10.1055/a-1044-1855. Epub 2019 Nov 25.
引用本文的文献
1
A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer.
EJNMMI Res. 2025 Jul 24;15(1):92. doi: 10.1186/s13550-025-01265-z.
2
Pharmacokinetics and dosimetry of [Lu]Lu-PSMA-617 and [Ga]Ga-PSMA-11 in Japanese patients with PSMA-positive mCRPC.
Ann Nucl Med. 2025 Jul 10. doi: 10.1007/s12149-025-02079-8.
3
The impact of patient hydration and forced diuresis on [F]PSMA-1007 urinary bladder uptake in PET/CT imaging.
EJNMMI Res. 2025 Jun 19;15(1):73. doi: 10.1186/s13550-025-01271-1.
4
Semiquantitative Analysis in PET/CT Imaging of Prostate Cancer.
J Clin Med. 2025 May 29;14(11):3828. doi: 10.3390/jcm14113828.
5
Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) in Initial Staging of Prostate Cancer Patients: The Beginning of a New Era.
Medicina (Kaunas). 2025 May 20;61(5):924. doi: 10.3390/medicina61050924.
6
PSMA PET Imaging in the Management of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radioligand Therapy.
Target Oncol. 2025 May 26. doi: 10.1007/s11523-025-01151-7.
7
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancer.
Oncologist. 2025 May 8;30(5). doi: 10.1093/oncolo/oyaf107.
8
The evolving role of positron emission tomography in precision prostate cancer biopsy.
Eur J Clin Invest. 2025 Aug;55(8):e70062. doi: 10.1111/eci.70062. Epub 2025 Apr 23.
9
MDT perspective: innovative applications of stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis. 2024 Nov 18. doi: 10.1038/s41391-024-00922-z.
10
Update on PSMA-based Prostate Cancer Imaging.
Semin Nucl Med. 2024 Nov;54(6):941-950. doi: 10.1053/j.semnuclmed.2024.10.004. Epub 2024 Oct 28.
本文引用的文献
1
Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial.
JAMA Oncol. 2021 Nov 1;7(11):1635-1642. doi: 10.1001/jamaoncol.2021.3771.
2
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
3
F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial.
Lancet. 2021 May 22;397(10288):1895-1904. doi: 10.1016/S0140-6736(21)00581-X. Epub 2021 May 7.
4
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with F-DCFPyL in Prostate Cancer Patients (OSPREY).
J Urol. 2021 Jul;206(1):52-61. doi: 10.1097/JU.0000000000001698. Epub 2021 Feb 26.
5
Diagnostic Performance of F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.
Clin Cancer Res. 2021 Jul 1;27(13):3674-3682. doi: 10.1158/1078-0432.CCR-20-4573. Epub 2021 Feb 23.
6
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET.
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1626-1638. doi: 10.1007/s00259-021-05245-y. Epub 2021 Feb 19.
7
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
JAMA Oncol. 2021 Apr 1;7(4):555-563. doi: 10.1001/jamaoncol.2020.7857.
8
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
9
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021.
J Natl Compr Canc Netw. 2021 Feb 2;19(2):134-143. doi: 10.6004/jnccn.2021.0008.
10
Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
J Urol. 2021 Jun;205(6):1663-1670. doi: 10.1097/JU.0000000000001596. Epub 2021 Feb 4.
Zotero 插件